Ono Pharmaceutical Future Growth
Future criteria checks 0/6
Ono Pharmaceutical's earnings are forecast to decline at 6.8% per annum while its annual revenue is expected to grow at 1.2% per year. EPS is expected to decline by 6.6% per annum. Return on equity is forecast to be 7.6% in 3 years.
Key information
-6.8%
Earnings growth rate
-6.6%
EPS growth rate
Pharmaceuticals earnings growth | 11.1% |
Revenue growth rate | 1.2% |
Future return on equity | 7.6% |
Analyst coverage | Good |
Last updated | 17 Dec 2024 |
Recent future growth updates
Ono Pharmaceutical Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 03Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 04Recent updates
The Market Doesn't Like What It Sees From Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Earnings Yet
Dec 16Is Ono Pharmaceutical (TSE:4528) A Risky Investment?
Nov 25Ono Pharmaceutical Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 03We Think Ono Pharmaceutical (TSE:4528) Can Stay On Top Of Its Debt
Aug 25Ono Pharmaceutical Co., Ltd. (TSE:4528) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 04There's No Escaping Ono Pharmaceutical Co., Ltd.'s (TSE:4528) Muted Earnings
Jun 24Ono Pharmaceutical (TSE:4528) Has Announced A Dividend Of ¥40.00
Mar 04Is There An Opportunity With Ono Pharmaceutical Co., Ltd.'s (TSE:4528) 42% Undervaluation?
Feb 27Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 525,199 | 73,376 | 80,476 | 111,588 | 12 |
3/31/2026 | 516,857 | 69,509 | 67,529 | 98,849 | 13 |
3/31/2025 | 489,699 | 62,237 | -4,487 | 68,371 | 12 |
9/30/2024 | 484,298 | 95,127 | 91,943 | 108,662 | N/A |
6/30/2024 | 500,331 | 120,953 | 105,249 | 121,111 | N/A |
3/31/2024 | 502,672 | 127,977 | 89,831 | 110,660 | N/A |
12/31/2023 | 498,070 | 127,611 | 91,301 | 106,044 | N/A |
9/30/2023 | 489,199 | 124,875 | 97,371 | 115,354 | N/A |
6/30/2023 | 460,481 | 115,064 | 98,429 | 116,894 | N/A |
3/31/2023 | 447,187 | 112,723 | 145,113 | 159,610 | N/A |
12/31/2022 | 428,951 | 111,555 | 137,391 | 149,495 | N/A |
9/30/2022 | 403,985 | 96,568 | 93,387 | 102,437 | N/A |
6/30/2022 | 380,720 | 85,922 | 78,395 | 88,151 | N/A |
3/31/2022 | 361,361 | 80,519 | 49,552 | 61,829 | N/A |
12/31/2021 | 345,781 | 73,558 | 38,233 | 53,343 | N/A |
9/30/2021 | 332,887 | 81,866 | 60,412 | 83,032 | N/A |
6/30/2021 | 321,734 | 78,003 | 47,401 | 70,321 | N/A |
3/31/2021 | 309,284 | 75,425 | 53,684 | 73,977 | N/A |
12/31/2020 | 302,054 | 74,364 | 53,088 | 72,011 | N/A |
9/30/2020 | 293,886 | 66,737 | 55,742 | 70,596 | N/A |
6/30/2020 | 293,351 | 64,870 | 58,824 | 78,232 | N/A |
3/31/2020 | 292,420 | 59,704 | 51,712 | 74,157 | N/A |
12/31/2019 | 290,736 | 60,233 | 43,202 | 73,947 | N/A |
9/30/2019 | 293,247 | 55,510 | 38,797 | 66,058 | N/A |
6/30/2019 | 291,374 | 52,633 | 32,152 | 58,850 | N/A |
3/31/2019 | 288,634 | 51,539 | 37,172 | 66,774 | N/A |
12/31/2018 | 284,463 | 51,978 | 42,500 | 67,269 | N/A |
9/30/2018 | 284,785 | 57,919 | 29,645 | 61,700 | N/A |
6/30/2018 | 272,165 | 53,746 | N/A | 48,716 | N/A |
3/31/2018 | 261,836 | 50,284 | N/A | 15,727 | N/A |
12/31/2017 | 256,522 | 54,760 | N/A | 28,754 | N/A |
9/30/2017 | 248,517 | 53,884 | N/A | 40,205 | N/A |
6/30/2017 | 246,953 | 53,887 | N/A | 53,650 | N/A |
3/31/2017 | 244,797 | 55,793 | N/A | 74,450 | N/A |
12/31/2016 | 236,710 | 48,270 | N/A | 44,743 | N/A |
9/30/2016 | 207,707 | 36,225 | N/A | 32,972 | N/A |
6/30/2016 | 183,345 | 29,206 | N/A | 16,805 | N/A |
3/31/2016 | 160,284 | 24,979 | N/A | 12,842 | N/A |
12/31/2015 | 140,927 | 16,449 | N/A | 29,716 | N/A |
9/30/2015 | 143,697 | 21,568 | N/A | 31,169 | N/A |
6/30/2015 | 139,663 | 19,521 | N/A | 30,488 | N/A |
3/31/2015 | 135,775 | 12,976 | N/A | 31,579 | N/A |
12/31/2014 | 137,592 | 17,663 | N/A | N/A | N/A |
9/30/2014 | 133,926 | 13,474 | N/A | 19,681 | N/A |
6/30/2014 | 137,146 | 16,787 | N/A | N/A | N/A |
3/31/2014 | 143,247 | 20,350 | N/A | 28,422 | N/A |
12/31/2013 | 145,946 | 21,574 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4528's earnings are forecast to decline over the next 3 years (-6.8% per year).
Earnings vs Market: 4528's earnings are forecast to decline over the next 3 years (-6.8% per year).
High Growth Earnings: 4528's earnings are forecast to decline over the next 3 years.
Revenue vs Market: 4528's revenue (1.2% per year) is forecast to grow slower than the JP market (4.2% per year).
High Growth Revenue: 4528's revenue (1.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4528's Return on Equity is forecast to be low in 3 years time (7.6%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 09:15 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ono Pharmaceutical Co., Ltd. is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Atsushi Seki | Barclays |
Koichi Mamegano | BofA Global Research |
Aaron Ho | CFRA Equity Research |